AIM:Omega-3脂肪酸补充剂心血管病二级预防证据不充分

2012-04-14 沐雨译 医学论坛网

  最新荟萃分析显示,Omega-3脂肪酸补充剂在有心血管病史的患者对于总体心血管事件二级预防的证据不充分。该荟萃分析4月9日在线发表于《内科医学文献》(Arch Intern Med)杂志。   研究者收集了1007篇文章,最终的分析纳入14项随机、双盲、安慰剂对照的临床试验,包含20485例既往有心血管病的患者。   分析表明,Omega-3脂肪酸补充剂并没有减少总体心

  最新荟萃分析显示,Omega-3脂肪酸补充剂在有心血管病史的患者对于总体心血管事件二级预防的证据不充分。该荟萃分析4月9日在线发表于《内科医学文献》(Arch Intern Med)杂志。

  研究者收集了1007篇文章,最终的分析纳入14项随机、双盲、安慰剂对照的临床试验,包含20485例既往有心血管病的患者。

  分析表明,Omega-3脂肪酸补充剂并没有减少总体心血管事件(相对危险0.99)、全因死亡率、心脏猝死、心肌梗死、充血性心力衰竭、短暂性脑缺血发作或卒中危险。心血管死亡危险有小幅降低(相对危险0.91,95%CI为0.84~0.99),但是排除主要方法学问题后此作用消失。

  另外,在以下的亚组分析中也没有显著的预防作用:乡村地区、岛屿或海滨区域、心血管病史、同时应用的药物、安慰剂种类、试验的方法学质量、治疗时程、二十碳五烯酸和二十二碳六烯酸的剂量,或仅用鱼油补充剂作为治疗。

  链接:

   Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease

  A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779106, encodeId=ab9a1e7910612, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Aug 19 06:31:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778730, encodeId=edcb1e78730c6, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Jun 10 07:31:00 CST 2012, time=2012-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644345, encodeId=1c511644345ab, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 24 05:31:00 CST 2012, time=2012-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779106, encodeId=ab9a1e7910612, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Aug 19 06:31:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778730, encodeId=edcb1e78730c6, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Jun 10 07:31:00 CST 2012, time=2012-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644345, encodeId=1c511644345ab, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 24 05:31:00 CST 2012, time=2012-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779106, encodeId=ab9a1e7910612, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Aug 19 06:31:00 CST 2012, time=2012-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778730, encodeId=edcb1e78730c6, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sun Jun 10 07:31:00 CST 2012, time=2012-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644345, encodeId=1c511644345ab, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 24 05:31:00 CST 2012, time=2012-10-24, status=1, ipAttribution=)]